KNSA - Company ID 0001730430
The table below shows Kiniksa Pharmaceuticals, Ltd.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $214.27M | $180.85M | $156.80M | $137.78M | $112.21M | $108.63M |
| Cost of revenue | $20.80M | $20.26M | $18.60M | $17.87M | $20.11M | $12.32M |
| Gross profit | - | - | - | - | - | - |
| R&D | $27.48M | $24.17M | $18.75M | $19.32M | $26.06M | $24.02M |
Kiniksa Pharmaceuticals, Ltd. reported annual revenue of $677.56M for fiscal year 2025. That is up 60.1% from $423.24M in fiscal 2024. Over the 5 fiscal years shown, annual revenue grew from $38.54M (FY 2021) to $677.56M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $61.15M |
| $49.10M |
| $46.86M |
| $43.53M |
| $46.40M |
| $42.40M |
| Operating income | $29.27M | $24.02M | $20.16M | $13.27M | -$9.66M | -$117.00K |
| Income tax | $10.09M | $8.72M | $5.04M | $7.03M | $5.49M | $6.21M |
| Net income | $22.59M | $18.43M | $17.83M | $8.54M | -$12.69M | -$3.91M |
| EPS (diluted) | $0.27 | $0.23 | $0.23 | $0.11 | -$0.18 | -$0.06 |